Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Merly Contratto, Jennifer Wu, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, United States
Author contributions: Wu J provided the concept, the outline, the structure, major references for this manuscript and provided critical revisions for this manuscript; Contratto M drafted the majority of the manuscript and incorporated several revisions based on feedback from Wu J; all authors approved the final manuscript.
Conflict-of-interest statement: There is no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. firstname.lastname@example.org
Telephone: +1-212-2636530 Fax: +1-212-2638210
Received: February 5, 2018
Peer-review started: February 7, 2018
First decision: March 8, 2018
Revised: March 14, 2018
Accepted: April 10, 2018
Article in press: April 11, 2018
Published online: May 15, 2018